c-MYC copy-number amplifications have been reported in up to 50% of ovarian carcinomas, whereas MYCL copy-number amplifications and gene overexpression have been reported in upwards of 21% of ovarian carcinomas [6,26,27,28,29,30,31,32,33,34,35,36,37]. Here, MYCL is linked to ovarian carcinoma.